Xeris Biopharma Holdings Q3 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $106.267M Beat $101.517M Estimate
Benzinga Newsdesk 1 hour ago
NewsEarningsEarnings Beats
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $106.267 million which
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $106.267 million which beat the analyst consensus estimate of $101.517 million by 4.68 percent. This is a 42.87 percent increase over sales of $74.380 million the same period last year.